Pioneering breakthrough therapeutics that overcome resistance and transform patient outcomes
Get StartedMetCure Therapeutics is positioned at a critical inflection point with three validated small-molecule drug discovery programs specifically targeting therapy-resistant and metastatic cancers entering IND-enabling studies, plus a complementary nutraceutical asset (ProFine®) for biochemically recurrent prostate cancer, generating near-term commercial revenue. We are seeking strategic partnerships and investment to accelerate clinical development and unlock significant market opportunity in oncology and prostate cancer wellness.
Validated Targets & Novel Mechanisms: Skp1-Skp2 degraders, EED-EZH2 inhibitors/degraders (PCT patent filed), and SLC7A11 ferroptosis inducers targeting chemoresistant cancers with 8+ therapeutic indications.
Patent Protection & Exclusivity: Granted US patents, PCT applications filed, and novel chemical scaffolds providing competitive moats and licensing opportunities.
Proven Leadership: Tenured faculty, NCI/NSF grant recipients, pharma executives, clinical oncology leaders and regulation experts with track records in drug development and commercialization.
Direct path to IND: IND-enabling studies underway with federal and state funding support. Proven roadmap to clinical trials and multi-billion dollar oncology markets.
Global oncology markets (advanced cancers, rare cancers) addressable by MetCure pipeline
Projected market share in focused indications within 5 years of market entry
Revenue potential by 2032 (conservative estimates based on market analysis)
Explore strategic partnership, licensing, and investment opportunities to accelerate breakthrough oncology therapeutics to patients in need.
Explore Opportunities